BRAF and colorectal cancer: A considerably greater armamentarium of targeted drugs had opened for more patients getting access to a matched treatment and could also provide benefit from mechanistically based drug combinations as illustrated by the efficacy of cobimetinib combined with vemurafenib in BRAF mutated colorectal cancer [28].